TransCode Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.63 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 27.60M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical...